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Abstract 
Topiramate is a sulfa-derivative antiepileptic drug which is also used for other 
indications such as essential tremor. A 79-year-old male was admitted to our center due 
to acute bilateral painless decline of vision. One month before admission, he had 
experienced essential tremor and treatment with topiramate 50 mg/day and propranolol 
40 mg/day. Best-corrected visual acuity was 20/800 OD and 20/600 OS. Both eyes had 
normal anterior chamber depths and irides. Intraocular pressure was 10 mm Hg in the 
right eye and 11 mm Hg in the left eye. Retinal examination showed notable choroidal 
detachments in all quadrants of the periphery, which were confirmed by 
ultrasonography. Refraction showed no myopic shift. The administration of topiramate 
was discontinued as a potential causative agent for this condition. During follow-up, 
choroidal detachment and visual acuity gradually resolved. In this study, we described 
the first case of isolated massive choroidal detachment induced by topiramate. 
 
Introduction 
Topiramate is a sulfa-derivative antiepileptic drug which is also used for other 
indications such as migraine, personality disorders, weight loss, neuropathic pain and, 
recently, essential tremor [1, 2]. The pharmacodynamic picture of this drug generally 
reflects the modulation of voltage-gated sodium and calcium channels, increase of Case Rep Ophthalmol 2011;2:251–255 
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GABAergic inhibition, blockage of glutamate receptors and mild carbonic anhydrase 
inhibition [3]. To date, several side effects of this drug are reported, of which ophthalmic 
manifestations are of special importance. The most clinically significant ophthalmic side 
effects are angle-closure glaucoma, myopic shift, diplopia and nystagmus. The precise 
mechanisms responsible for such adverse effects are, however, not completely understood 
[4]. 
Serous choroidal detachment (transudation of fluid into the suprachoroidal space) may 
be due to globe hypotony of any etiology or exudation of serum caused by inflammation 
or other causes [5]. Choroidal detachment is generally known as a probable complication 
of sensitized eyes following surgery. Typically, these cases are concurrently treated with 
ocular hypotensive drugs [6]. Moreover, there are some instances in which the occurrence 
of choroidal detachment is not explainable by common mechanisms [5]. 
To our knowledge, massive choroidal detachment following the administration of 
topiramate has never been described in previous case reports. The purpose of this report 
was to illustrate the clinical and paraclinical features of a patient who experienced the 
above-mentioned adverse event. We also aimed to discuss the possible pathogenic links of 
topiramate by comparing the features of our case with those of cases previously reported 
in the literature. 
Case Report 
A 79-year-old male was admitted to our center for further evaluation of acute bilateral painless 
decline of vision. The patient’s past clinical history included 80 mg/day aspirin intake due to unstable 
angina for 11 years. He denied any past history of smoking or addiction. 
On neurological examination, mental status was found to be normal. The patient had no significant 
neurological disorder until 1 month before admission, when he experienced essential tremor. As a 
result, treatment with topiramate 50 mg/day and propranolol 40 mg/day was started 2 weeks before his 
admission due to ophthalmic symptoms. This treatment was prescribed by a neurologist. 
He underwent uncomplicated cataract surgery 11 years ago for the right eye and 9 years ago for the 
left eye, and both eyes had intraocular lenses. He had no clinical history of glaucoma surgery or anti-
glaucoma medications. 
On ophthalmologic examination, best-corrected visual acuity was 20/800 OD and 20/600 OS. The 
eyelids showed meibomian gland dysfunction. Both eyes showed mild hyperemia and had normal 
anterior chamber depths and irides. Pupillary reactions to light and near stimuli were normal, and no 
pupillary afferent defect was present. Ocular motility was normal. Intraocular pressure was 10 mm Hg 
in the right and 11 mm Hg in the left eye. Anterior vitreous examination showed no abnormality. 
Retinal examination revealed posterior pole drusen compatible with mild dry age-related macular 
degeneration and notable choroidal detachments in all quadrants of the periphery (fig. 1), which were 
confirmed by ultrasonography (fig. 2). Refraction showed no myopic shift. 
The administration of topiramate was discontinued as a potential causative agent for this condition; 
however, we did not reduce the dosage of propranolol. We continued monitoring the patient’s status 
daily. Within 3 days, visual acuity improved to 20/200 OD and 20/60 OS. This improvement continued 
until day 7, when visual acuity gradually exceeded to 20/25 OD and 20/30 OS. By the end of day 7, 
choroidal detachment resolved as well. Case Rep Ophthalmol 2011;2:251–255 
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Discussion 
We described the first case of isolated massive choroidal detachment induced by 
topiramate. However, it is worth noting that in a study by the National Registry of Drug-
Induced Ocular Side Effects, 9 cases of suprachoroidal effusion were concisely mentioned 
regardless of the severity of their complication. The data on these subjects were extracted 
from the records of the World Health Organization or other related/similar organizations 
[4]. Nevertheless, to the best of our knowledge, neither precise features of these cases, e.g. 
the severity of effusion, were published elsewhere, nor any of them were specified to 
present massive choroidal detachment. 
A review of the ophthalmology literature reveals that, to date, there are several reports 
describing bilateral angle closure following topiramate intake [4, 7–9]. Our patient did 
not exhibit myopic changes or a shallow anterior chamber, although such side effects have 
been frequently observed with the use of this drug. 
The term ‘ciliochoroidal effusion syndrome’ was first proposed by Ikeda et al. [10] to 
describe the phenomena induced by topiramate and other sulfa derivatives. This 
syndrome represents a category of symptoms including ciliochoroidal effusion, forward 
displacement of the lens-iris diaphragm and, consequently, angle narrowing and myopic 
shift. Accordingly, in our case choroidal effusion without development of angle closure or 
myopic shift could be due to lack of crystalline lens. 
As mentioned previously, the main cause of choroidal detachment is generally believed 
to be ocular hypotony following surgical procedures [6]. In our literature review, we could 
identify an interesting case by Doherty et al. [11] that shares decisive common features 
with ours. This patient was reported to manifest bilateral choroidal detachment after 
administration of topical dorzolamide. Taking together, four main similarities are worth 
noting: (1) both patients had a past history of uncomplicated cataract surgery; (2) 
intraocular pressure was within normal limits in both patients; (3) dorzolamide and 
topiramate are both sulfa-derivative drugs, and (4) similar to dorzolamide which is a 
carbonic anhydrase antagonist, topiramate is also suggested to be ‘a mild carbonic 
anhydrase inhibitor’ [3]. Accordingly, the authors concluded that the cause of choroidal 
detachment is not always hypotony and postulated that it may also be due to 
hypersensitivity to dorzolamide. Our case provides further evidence in favor of this 
hypothesis, and this raises the question whether the cause of choroidal detachment in our 
case was hypersensitivity to topiramate as this is a sulfa-derivative drug as well. From 
another point of view, it is well known that carbonic anhydrase antagonists can cause 
choroidal detachment [12], and this may explain why the administration of dorzolamide 
and topiramate results in this adverse effect. 
As a conclusion, we propose that the administration of topiramate and perhaps other 
sulfa-derivative drugs might be eligible to be added as a differential diagnosis of choroidal 
detachment. 
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Fig. 1. Fundus photographies of both eyes showing massive choroidal detachment. a Right eye. 
b, c Left eye. 
 
 
 
Fig. 2. B scan ultrasonography confirming massive choroidal detachment in both eyes. 
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